EPS for TG Therapeutics, Inc. (TGTX) Expected At $-0.46; Cbre Clarion Securities Has Trimmed By $743,431 Its Tc Pipelines L.P. (TCP) Stake

April 17, 2018 - By Nellie Frank

Cbre Clarion Securities Llc decreased Tc Pipelines L.P. (TCP) stake by 23.84% reported in 2017Q4 SEC filing. Cbre Clarion Securities Llc sold 14,027 shares as Tc Pipelines L.P. (TCP)’s stock declined 34.01%. The Cbre Clarion Securities Llc holds 44,823 shares with $2.38M value, down from 58,850 last quarter. Tc Pipelines L.P. now has $2.41 billion valuation. The stock increased 1.68% or $0.56 during the last trading session, reaching $33.8. About 247,341 shares traded. TC PipeLines, LP (NYSE:TCP) has declined 41.45% since April 17, 2017 and is downtrending. It has underperformed by 53.00% the S&P500.

Analysts expect TG Therapeutics, Inc. (NASDAQ:TGTX) to report $-0.46 EPS on May, 4.They anticipate $0.06 EPS change or 11.54% from last quarter’s $-0.52 EPS. After having $-0.46 EPS previously, TG Therapeutics, Inc.’s analysts see 0.00% EPS growth. The stock increased 3.61% or $0.475 during the last trading session, reaching $13.625. About 311,237 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 23.61% since April 17, 2017 and is uptrending. It has outperformed by 12.06% the S&P500.

Investors sentiment increased to 2 in Q4 2017. Its up 0.79, from 1.21 in 2017Q3. It increased, as 12 investors sold TG Therapeutics, Inc. shares while 14 reduced holdings. 17 funds opened positions while 35 raised stakes. 35.20 million shares or 0.20% more from 35.13 million shares in 2017Q3 were reported. Jpmorgan Chase And holds 559,553 shares. Guggenheim Cap Limited Liability Corp, a Illinois-based fund reported 151,387 shares. Raymond James Financial Advsrs reported 138,384 shares. Ubs Asset Mngmt Americas invested in 1.07 million shares or 0.01% of the stock. Deutsche Retail Bank Ag, a Germany-based fund reported 117,990 shares. The Georgia-based Invesco has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Sei Investments holds 44 shares. Columbus Circle Invsts reported 0.08% stake. Metropolitan Life Co Ny invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Dupont Capital Mgmt invested 0.01% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Gam Ag reported 98,600 shares or 0.02% of all its holdings. Schwab Charles Investment Mngmt owns 266,970 shares for 0% of their portfolio. Moreover, Barclays Public Ltd Com has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 11,251 shares. D E Shaw & reported 88,271 shares. 133,393 were reported by Gp One Trading Limited Partnership.

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 21 analyst reports since August 12, 2015 according to SRatingsIntel. FBR Capital maintained the stock with “Buy” rating in Friday, March 9 report. The rating was reinitiated by H.C. Wainwright with “Buy” on Wednesday, August 12. On Tuesday, March 7 the stock rating was maintained by H.C. Wainwright with “Buy”. Zacks upgraded it to “Hold” rating and $19 target in Wednesday, August 12 report. FBR Capital maintained the shares of TGTX in report on Thursday, June 15 with “Buy” rating. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Friday, February 2. The stock has “Buy” rating by H.C. Wainwright on Tuesday, November 14. As per Monday, December 11, the company rating was maintained by FBR Capital. SunTrust initiated the stock with “Buy” rating in Friday, May 27 report. As per Monday, December 11, the company rating was maintained by H.C. Wainwright.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $996.54 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

Since December 29, 2017, it had 0 insider buys, and 1 sale for $272,051 activity. 32,006 shares were sold by Power Sean A, worth $272,051.

Cbre Clarion Securities Llc increased Crown Castle International Cor (NYSE:CCI) stake by 213,544 shares to 393,644 valued at $43.70 million in 2017Q4. It also upped Hudson Pacific Properties (NYSE:HPP) stake by 102,114 shares and now owns 6.12 million shares. American Electric Power Co. In (NYSE:AEP) was raised too.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.10, from 0.81 in 2017Q3. It is positive, as 13 investors sold TCP shares while 45 reduced holdings. 20 funds opened positions while 33 raised stakes. 45.12 million shares or 12.28% more from 40.18 million shares in 2017Q3 were reported. Solaris Asset Management Limited Liability Co owns 500 shares. State Street stated it has 0% in TC PipeLines, LP (NYSE:TCP). Jpmorgan Chase And stated it has 1.09M shares or 0.01% of all its holdings. Asset Inc stated it has 23,250 shares or 0.02% of all its holdings. Royal Bancorporation Of Canada invested in 31,023 shares. Cap Advsr Limited Liability Com invested in 7,421 shares. Delta Asset Management Ltd Liability Corporation Tn accumulated 7 shares or 0% of the stock. Mariner Limited Liability Company holds 99,860 shares. Manufacturers Life Insur Co The owns 2,208 shares. Ing Groep Nv holds 13,000 shares. Moreover, Advisory Rech has 2.02% invested in TC PipeLines, LP (NYSE:TCP) for 2.30M shares. Estabrook Cap Management invested 0.01% of its portfolio in TC PipeLines, LP (NYSE:TCP). 3,050 are owned by First Manhattan. Williams Jones And Assoc Ltd Liability invested in 0.01% or 8,504 shares. 4,350 were reported by Highland Limited Com.

Analysts await TC PipeLines, LP (NYSE:TCP) to report earnings on May, 3. They expect $1.08 EPS, up 2.86% or $0.03 from last year’s $1.05 per share. TCP’s profit will be $77.01M for 7.82 P/E if the $1.08 EPS becomes a reality. After $0.77 actual EPS reported by TC PipeLines, LP for the previous quarter, Wall Street now forecasts 40.26% EPS growth.

Among 12 analysts covering TC Pipelines (NYSE:TCP), 2 have Buy rating, 3 Sell and 7 Hold. Therefore 17% are positive. TC Pipelines had 32 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of TC PipeLines, LP (NYSE:TCP) has “Buy” rating given on Tuesday, November 7 by UBS. As per Friday, May 27, the company rating was maintained by JP Morgan. The stock of TC PipeLines, LP (NYSE:TCP) earned “Underperform” rating by Bank of America on Wednesday, March 21. The stock of TC PipeLines, LP (NYSE:TCP) earned “Neutral” rating by UBS on Monday, March 19. The firm has “Buy” rating given on Monday, September 25 by RBC Capital Markets. The company was maintained on Sunday, October 29 by RBC Capital Markets. Morgan Stanley maintained the stock with “Underweight” rating in Friday, March 23 report. Citigroup maintained it with “Buy” rating and $43 target in Wednesday, March 28 report. RBC Capital Markets upgraded TC PipeLines, LP (NYSE:TCP) on Monday, December 12 to “Outperform” rating. The firm earned “Neutral” rating on Wednesday, July 27 by Citigroup.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Nellie Frank

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: